Harbin Gloria Pharma pay $380 million to acquire an 85% stake in Shanxi Powerdone, which makes chemical drugs and compound preparations.

To pay for the transaction, Gloria will raise $960 million in a private placement.

In addition, Gloria will allocate another $183 million in capex to several company infrastructure improvements.

And, two months ago, Gloria spent $24 million to acquire the remaining 30% stake in Guangzhou Xinhuacheng Biotech, gaining a production base for ginkgolide B injections.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio